[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"conduction-disturbances\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:conduction-disturbances":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100373222","prospective-validation-of-a-pre-specified-algorithm-for-the-management-of-conduction-disturbances-following-tavr-100373222",false,"NCT04139616","Prospective Validation of a Pre-Specified Algorithm for the Management of Conduction Disturbances Following TAVR","Prospective Validation of a Pre-Specified Algorithm for the Management of Conduction Disturbances Following Transcatheter Aortic Valve Replacement. The PROMOTE Study","PROMOTE","Inclusion Criteria:\n\n-Patients with aortic valve disease undergoing transcatheter aortic valve replacement\n\nExclusion Criteria:\n\n* Prior permanent pacemaker\n* Failure to provide signed informed consent for data collection\n* Impossibility for a follow-up\n* Unwillingness to follow the pre-specified strategy for the management of conduction disturbances",true,"ALL","18 Years",{"count":21,"type":22},2000,"ESTIMATED","1 Year","OBSERVATIONAL","The high incidence and variety of conduction disturbances post-TAVR represents a major challenge in the periprocedural management of TAVR recipients. Despite the growing body of knowledge on this topic, the large variability in the management of these complications has translated into a high degree of uncertainty regarding the most appropriate treatment of a large proportion of such patients. The implementation of a pre-specified treatment strategy translating into a more uniform practice regarding the management of conduction disturbances post-TAVR applied to a large cohort of patients would permit to identify the benefits and drawbacks of each specific aspect of the treatment algorithm proposal. This may also help to improve both the management and clinical outcomes of the complex group of patients with conduction disturbances associated with TAVR. In the end, the final objective of a pre-specified strategy for managing conduction disturbances post-TAVR should be to obtain a low rate of PPM without increasing the risk of sudden death or life threatening arrhythmic events following hospital discharge, and all this while avoiding an excessive prolongation of the hospitalization period following the TAVR procedure.",[27,28,29],"Conduction Disturbances","Transcatheter Aortic Valve Replacement","Permanent Pacemaker Implantation",[31,32,33,34,35,36,37],"atrioventricular block","complete heart block","high-degree atrioventricular block","intraventricular conduction delay","left bundle branch block","Permanent pacemaker implantation","Right bundle branch block","RECRUITING","2026-05-28",{"date":41,"type":42},"2026-06-01","ACTUAL",{"date":44,"type":42},"2020-02-25",{"date":46,"type":22},"2027-12-25",{"name":48,"class":49},"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":50},"100220916","ambulatory-electrocardiographic-monitoring-for-the-detection-of-high-degree-atrio-ventricular-block-in-patients-with-new-onset-persistent-left-bundle-branch-block-after-transcatheter-aortic-valve-implantation-the-mare-study-100220916","NCT02153307","Ambulatory Electrocardiographic Monitoring for the Detection of High-Degree Atrio-Ventricular Block in Patients With New-onset PeRsistent LEft Bundle Branch Block After Transcatheter Aortic Valve Implantation. The \"MARE\" Study","MARE","Inclusion Criteria:\n\n-Patients undergoing TAVI with either balloon or self-expandable valves who develop new-onset LBBB persistent at hospital discharge, at least 3 days after the procedure\n\nExclusion Criteria:\n\n* Failure to provide informed consent\n* Baseline pacemaker\u002Fdefibrillator or pacemaker\u002Fdefibrillator implanted during the hospitalization period following the TAVI procedure\n* Pre-existing complete LBBB\n* Patients with a life-expectancy of less than 2 years",{"count":59,"type":22},80,"INTERVENTIONAL",[62],"NA","The purpose of this study is to determine the incidence and predictors of high degree or complete atrioventricular block (AVB) (paroxysmal or persistent) in patients with new-onset persistent left bundle branch block (NOP-LBBB) following transcatheter aortic valve implantation (TAVI) and to evaluate the usefulness of the Reveal LINQ® insertable Cardiac Monitor (ICM) (Medtronic, Inc., Minneapolis, USA) for the detection of significant arrhythmias in patients with NOP-LBBB following TAVI.",[65,27],"Aortic Valve Disease","2026-03-23",{"date":68,"type":42},"2026-03-24",{"date":70,"type":4},"2014-01",{"date":72,"type":22},"2026-07",{"name":48,"class":49},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":60,"phases":84,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":50},"100553057","reversibility-of-cardiac-conduction-disturbances-following-tavi-100553057","NCT06481137","Reversibility of Cardiac Conduction Disturbances Following TAVI","InvesTigAtion of the reVersIbility of caRdiac Conduction disturbancEs Following Percutaneous Aortic ValvE Implantation in Patients With Severe aoRtic StEnosis: The TAVI-REVERSE Study","TAVI-REVERSE","Inclusion Criteria:\n\n* Patients with indication for electrophysiological (EP) study after TAVI implantation according to European Guidelines. Patients must have persistent electrocardiographic conduction disturbances (ECG-CDs) that are present from day 2 after TAVI implantation (≥ 48h post-procedure):\n* De novo LBBB with QRS complex \\>150ms and\u002For PR interval ≥240ms.\n* QRS widening or post-procedural PR lengthening \\> 20ms in patients with baseline ECG-CDs.\n\nExclusion Criteria:\n\n* Patients with previous pacemaker or implantable defibrillator.\n* Patients with baseline complete right bundle branch block.\n* Patients in need of cardiac resynchronization or physiological stimulation following TAVI.\n* Valve-in-valve procedures.\n* TAVI procedures in patients with severe aortic insufficiency.\n* Inability to sign the informed consent form.",{"count":83,"type":22},209,[62],"The management of patients with conduction disturbances (CDs) after transcatheter aortic valve implantation (TAVI) is unclear, especially in those with de novo electrocardiographic CDs (ECG-CDs) such as left bundle branch block.\n\nIn this study, the investigators will evaluate the incidence of retrogradation of infra-Hisian CDs in patients with de novo ECG-CDs and positive electrophysiological study (EPS) 3-7 days following TAVI. In addition, the investigators will evaluate the need for cardiac pacing and the incidence of clinical events in patients with negative EPS performed 3-7 days following TAVI.\n\nIn this multicenter, longitudinal, prospective study, patients with clinical indication of EP study due to new-onset ECG-CDs after TAVI will be included. A permanent pacemaker will be implanted in patients with positive EPS and a second EPS will be performed in 30-45 days. Additionally, these patients will undergo 4-week continuous monitoring using the ePatch (Philips) long-term Holter recorder, to identify episodes of paroxysmal complete atrioventricular block. Patients with negative EP study will undergo clinical follow-up and continuous monitoring for 4 weeks.",[87,88,27],"Aortic Stenosis","Transcatheter Aortic Valve Implantation",[90,88,27],"Aortic stenosis","2024-06-25",{"date":93,"type":42},"2024-07-01",{"date":95,"type":42},"2024-06-17",{"date":97,"type":22},"2026-12-31",{"name":99,"class":49},"Institut d'Investigació Biomèdica de Bellvitge"]